Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Clinical Results from the MolecuLight i:X® Fluorescence Imaging System are Featured in Two Clinical Talks and Seven Posters at the SAWC Fall 2019 Annual Conference

October 11, 2019 GMT
MolecuLight Inc. (CNW Group/MolecuLight)
MolecuLight Inc. (CNW Group/MolecuLight)

Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care
Fluorescence Imaging Device for Chronic Wound Management

LAS VEGAS and TORONTO, Oct. 11, 2019 /PRNewswire/ - MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging device are featured prominently in 2 presentations and 7 clinical posters at the Symposium on Advanced Wound Care (SAWC) Fall 2019, one of North America’s leading wound healing conferences. The conference is being held at Caesars Palace, Las Vegas, Nevada from Oct. 12 - 14, 2019 and features the foremost experts in wound care across the entire wound care team—physicians, nurses, physical therapists, researchers, scientists, and podiatrists – in a setting to share best practices in order to improve patient outcomes.

“SAWC Fall is a major conference, sharing the latest innovations in wound healing and we are proud of the many talks and posters citing the significant clinical results derived using our MolecuLight i:X fluorescence imaging platform,” said Anil Amlani, MolecuLight’s CEO. “Our customers, across a multitude or trials and case studies, are showing significant improvement in clinical results across the wound care pathway when supplementing clinical signs and symptoms with real-time data provided by the fluorescence-guided detection of bacteria from the MolecuLight i:X. Clinical results include improvements in screening, targeted cleaning and debridement, targeted sampling, as well as guidance and optimization of treatment.”

The two oral presentations at SAWC Fall citing the MolecuLight i:X fluorescence imaging device are:

The seven clinical presentations citing the MolecuLight i:X will be presented on Sunday, October 13, 2019 from 8:00 am – 6:15 pm and include:

In addition to the presentations, hands-on demonstrations of the i:X device are being offered at the MolecuLight Booth #441 in the Exhibit Hall in Octavius Ballroom, Caesars Palace.

About MolecuLight Inc.

MolecuLight Inc. ( www.moleculight.com ) is a privately owned Canadian medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical and commercial markets. MolecuLight’s initial product and accessories, the MolecuLight i:X®, delivers a real-time handheld fluorescence imaging solution for the global wound care market. It provides clinicians with new information about the fluorescent characteristics of wounds to assist clinicians in making improved diagnostic and treatment decisions. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

View original content to download multimedia: http://www.prnewswire.com/news-releases/clinical-results-from-the-moleculight-ix-fluorescence-imaging-system-are-featured-in-two-clinical-talks-and-seven-posters-at-the-sawc-fall-2019-annual-conference-300936997.html

SOURCE MolecuLight